These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3728282)

  • 41. The effect of quinidine on electrical energy required for ventricular defibrillation.
    Woolfolk DI; Chaffee WR; Cohen W; Neville JF; Abildskov JA
    Am Heart J; 1966 Nov; 72(5):659-63. PubMed ID: 5923048
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation.
    Echt DS; Black JN; Barbey JT; Coxe DR; Cato E
    Circulation; 1989 May; 79(5):1106-17. PubMed ID: 2469545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antifibrillatory drugs: the case for bretylium tosylate.
    Dronen SC
    Ann Emerg Med; 1984 Sep; 13(9 Pt 2):805-7. PubMed ID: 6476547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Life threatening ventricular dysrhythmias: intervention with bretylium tosylate.
    Sullivan HE; Wehner RJ
    AANA J; 1983 Jun; 51(3):284-9. PubMed ID: 6613506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bretylium: relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias.
    Duff HJ; Roden DM; Yacobi A; Robertson D; Wang T; Maffucci RJ; Oates JA; Woosley RL
    Am J Cardiol; 1985 Feb; 55(4):395-401. PubMed ID: 3969876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of bretylium on intracellular cardiac action potentials in relation to its anti-arrhythmic and local anaesthetic activity.
    Papp JG; Vaughan Williams EM
    Br J Pharmacol; 1969 Oct; 37(2):380-90. PubMed ID: 5348427
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of bretylium in prehospital ventricular fibrillation.
    Harrison EE; Amey BD
    Am J Emerg Med; 1983 Jul; 1(1):1-6. PubMed ID: 6680596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bretylium tosylate in patients with acute myocardial infarction.
    Torresani J
    Am J Cardiol; 1984 Jul; 54(2):20A-25A. PubMed ID: 6464996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The effect of bretylium tosylate on ventricular arrhythmias in patients with acute myocardial infarction].
    Kochmański M; Rdzanek H; Zochowski RJ
    Pol Tyg Lek; 1992 Oct 5-12; 47(40-41):901-4. PubMed ID: 1341893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemical ventricular defibrillation in severe accidental hypothermia.
    Danzl DF; Sowers MB; Vicario SJ; Thomas DM; Miller JW
    Ann Emerg Med; 1982 Dec; 11(12):698-9. PubMed ID: 7149370
    [No Abstract]   [Full Text] [Related]  

  • 51. Experimental and clinical pharmacology of bretylium tosylate in acute myocardial infarction: a 15-year journey.
    Puddu PE; Jouve R; Saadjian A; Torresani J
    J Pharmacol; 1986; 17(3):223-43. PubMed ID: 3795968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical pharmacokinetics of intravenous and oral bretylium tosylate in survivors of ventricular tachycardia or fibrillation: clinical application of a new assay for bretylium.
    Anderson JL; Patterson E; Wagner JG; Johnson TA; Lucchesi BR; Pitt B
    J Cardiovasc Pharmacol; 1981; 3(3):485-99. PubMed ID: 6168830
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bretylium tosylate and electrically induced cardiac arrhythmias during hypothermia in dogs.
    Orts A; Alcaraz C; Delaney KA; Goldfrank LR; Turndorf H; Puig MM
    Am J Emerg Med; 1992 Jul; 10(4):311-6. PubMed ID: 1616517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vagally-mediated atrial fibrillation in dogs: conversion with bretylium tosylate.
    Goldberger AL; Pavelec RS
    Int J Cardiol; 1986 Oct; 13(1):47-55. PubMed ID: 3771001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemical ventricular defibrillation of the human heart with bretylium tosylate.
    Sanna G; Arcidiacono R
    Am J Cardiol; 1973 Dec; 32(7):982-7. PubMed ID: 4757239
    [No Abstract]   [Full Text] [Related]  

  • 56. A method for quantitating antifibrillatory effects of drugs after coronary reperfusion in dogs: improved outcome with bretylium.
    Wenger TL; Lederman S; Starmer CF; Brown T; Strauss HC
    Circulation; 1984 Jan; 69(1):142-8. PubMed ID: 6689638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Electrophysiologic effects of bretylium on canine ventricular muscle during acute ischemia and reperfusion.
    Fujimoto T; Hamamoto H; Peter T; McCullen A; McCullen A; Melvin N; Mandel WJ
    Am Heart J; 1983 Jun; 105(6):966-72. PubMed ID: 6858845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death.
    Holland K; Patterson E; Lucchesi BR
    Am Heart J; 1983 May; 105(5):711-7. PubMed ID: 6846113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The clinical pharmacology of antiarrhythmic drugs. Part II: Quinidine, propranolol, diphenylhydantoin, and bretylium.
    Levitt B; Borer JS; Sarapa A
    Cardiovasc Nurs; 1974; 10(6):27-31. PubMed ID: 4498549
    [No Abstract]   [Full Text] [Related]  

  • 60. Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model.
    Dorian P; Wang M; David I; Feindel C
    Circulation; 1991 Feb; 83(2):614-21. PubMed ID: 1991379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.